Form 4: Edwards Lifesciences Executive Trades EW Stock

Daniel J. Lippis, a Corporate Vice President at Edwards Lifesciences Corp, executed a Rule 10b5-1 trading plan involving the acquisition and disposition of company stock.

Summary

• Daniel J. Lippis, Corporate Vice President, TAVR at Edwards Lifesciences Corp, engaged in stock transactions on June 30, 2026.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan.
• Lippis acquired 619 shares of common stock at an average price of $72.68 per share.
• Lippis also disposed of 619 shares of common stock at a weighted average sale price of $91.40 per share.
• Following these transactions, Lippis beneficially owns 40,410.9103 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves insider transactions, the execution under a Rule 10b5-1 plan suggests a pre-determined strategy rather than a reaction to new information, making it neither strongly positive nor negative.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned and potentially less market-sensitive trading activity.
• The acquisition of shares at a lower price ($72.68) and sale at a higher price ($91.40) suggests a profitable execution within the plan.
• The reporting person continues to hold a significant number of shares (40,410.9103) after the reported transactions.

Negatives

• The disposal of company stock by a corporate officer, even under a plan, can sometimes be perceived negatively by the market.
• The weighted average sale price of $91.40 is higher than the acquisition price of $72.68, indicating a net sale of shares at a profit.

Risks

• The filing does not explicitly mention any risks associated with these transactions, as it is a standard disclosure of insider trading activity under a pre-existing plan.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions executed under a trading plan.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026.
• The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by executives at Edwards Lifesciences (EW) is common practice to diversify holdings or manage personal finances without appearing to trade on material non-public information. The specific prices and volume are typical for executive-level trades.

Stakeholder Impact

• Shareholders: The sale of stock by an executive, even under a plan, may lead to minor short-term market perception shifts, though the Rule 10b5-1 plan mitigates concerns about insider trading.
• Employees: The transaction does not directly impact employees but reflects standard executive compensation and equity management practices.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• The reporting person may continue to execute trades under the Rule 10b5-1 plan.
• Further Form 4 filings will be made if additional transactions occur.

Key Dates

Keywords

Form 4, Insider Trading, Edwards Lifesciences, EW, Rule 10b5-1, Stock Transaction, Beneficial Ownership, Executive Trading